- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib: First Global Approval
Authors
Keywords
Thyroid Cancer, Sorafenib, Fibroblast Growth Factor Receptor, Differentiate Thyroid Cancer, Breast Cancer Resistant Protein
Journal
DRUGS
Volume 75, Issue 5, Pages 553-560
Publisher
Springer Nature
Online
2015-03-20
DOI
10.1007/s40265-015-0383-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
- (2014) Noriyuki Koyama et al. BMC CANCER
- Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
- (2014) Robert C. Shumaker et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
- (2014) Robert C. Shumaker et al. CLINICAL DRUG INVESTIGATION
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas
- (2014) Anne-Charlotte Dubbelman et al. INVESTIGATIONAL NEW DRUGS
- Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration
- (2014) Robert Shumaker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization
- (2014) Kiyoshi Okamoto et al. ACS Medicinal Chemistry Letters
- Advances in thyroid cancer treatment: latest evidence and clinical potential
- (2014) T. Alonso-Gordoa et al. Therapeutic Advances in Medical Oncology
- Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
- (2013) M Nishio et al. BRITISH JOURNAL OF CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
- (2011) Hilary Glen et al. BMC CANCER
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
- (2011) Skjalg Bruheim et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More